Transamerica Life Insurance Fit Review for Epilepsy and Seizure Disorders

Research Snapshot

Why Transamerica Qualified for This Study

Questions This Section Answers

• Is Transamerica a good choice for life insurance for epilepsy and seizure disorders?
• Why did AI platforms rank Transamerica so highly for epilepsy life insurance?

Transamerica qualified because it was named by six of the seven platforms during ranking discovery and finished second overall, with three platforms placing it first (anthropic, google, grok) and one placing it fifth (perplexity). No other carrier in this study combined that mention share with a product set that spans simplified-issue permanent coverage and fully underwritten term.

The qualification rests on two independent threads. First, independent reviewers repeatedly describe Transamerica as accommodating toward epilepsy, including a documented history of covering applicants declined elsewhere and greater flexibility on tonic-clonic seizures ^[1]. Second, Transamerica's own materials show relevant products: a Final Expense Solutions Portfolio covering $1,000–$50,000 for ages 0–85 with a guaranteed level premium, and a $25,000 maximum face amount for Easy Solution at ages 18–80 (official:C1).

That combination is why platforms treated it as worth considering. It is not evidence that Transamerica prices or underwrites epilepsy better than every competitor. This review covers Transamerica only for this use case, not as a general company assessment; the broader field is tracked in the Life Insurance for Epilepsy and Seizure Disorders consensus index.

The Product, Model, Plan, or Service Most Relevant to Life Insurance for Epilepsy and Seizure Disorders

Questions This Section Answers

• Which Transamerica plan should a buyer with epilepsy choose if they need $25,000 or less of permanent coverage?
• Is Transamerica Trendsetter Super term life available to applicants with a seizure disorder?

Two Transamerica paths matter for this buyer, and they serve different needs.

The Final Expense Solutions Portfolio is the simplified-issue route. It includes Immediate Solution, 10-Pay Solution, and Easy Solution, advertises coverage from $1,000 to $50,000, and uses Express Protect underwriting through an electronic application with potential same-day approval and no exams or labs ^[4]. Easy Solution uses health questions rather than a medical exam, and Transamerica states not everyone qualifies ^[5]. One independent source describes FE Express Solution as fully digital with policy delivery in as little as 10 minutes ^[6].

The Trendsetter Super Series is the fully underwritten term route. It offers 10-, 15-, 20-, 25-, and 30-year guarantee periods with level premiums that increase after the initial guarantee period, and eligibility and premiums remain subject to underwriting ^[7]. A point-of-sale program lists Trendsetter Super amounts of $25,000–$99,999 and Trendsetter LB amounts up to $249,999 for specified age bands, with additional underwriting possible ^[9]. Independent reviews describe Trendsetter Super coverage up to $2 million without a medical exam for qualifying applicants ^[10] and term availability from $25,000 to $1 million ^[11].

Indexed Universal Life is also offered for eligible applicants, with product availability and eligibility varying ^[12], but no reviewed source documents how seizure history affects IUL eligibility.

What the AI Platforms Agreed About

Questions This Section Answers

• What do AI platforms agree on about Transamerica for epilepsy life insurance?
• Does Transamerica offer both no-exam final expense and fully underwritten term life for seizure disorder applicants?

Platforms agreed on four points.

First, Transamerica offers multiple product pathways for this buyer. All seven platform outputs describe either final expense, term, or both, and the relevant-product lists overlap heavily across platforms.

Second, simplified-issue final expense avoids a medical exam. Transamerica markets no-exam final expense with accelerated underwriting ^[13], and independent reviews confirm no exam for whole life and final expense policies ^[14].

Third, seizure history is a real underwriting input. Transamerica states underwriting considers age, health, medical history, medications, and lifestyle ^[16], and independent guidance identifies seizure type, frequency, time since last seizure, medication compliance, neurological evaluation, and driving restrictions as material factors ^[17].

Fourth, term conversion is available. Most Transamerica term policies include conversion options to permanent coverage without new underwriting ^[22], and Trendsetter Super policies include a conversion option with a deadline at the end of the initial term or age 70, or 75 for preferred plus ^[23].

Agreement among platforms reflects shared source material, not verified product quality.

Where the AI Platforms Disagreed or Were Uncertain

Questions This Section Answers

• Do AI platforms disagree about how Transamerica underwrites epilepsy?
• Is Transamerica's epilepsy underwriting criteria publicly available?

Fit ratings diverged. Grok rated Transamerica a strong fit, anthropic and google rated it good, and openai, perplexity, kimi, and deepseek rated it mixed. That split is the single clearest signal in this study: platforms read the same company but weighted the missing underwriting detail differently.

The sharpest conflict concerns published epilepsy criteria. Perplexity cited Transamerica underwriting guides that explicitly reference epilepsy and seizure history, with outcomes ranging from postpone or decline to standard and preferred depending on seizure history ^[25]. Google cited a Transamerica field underwriting guide showing standard to table ratings for petit mal and grand mal epilepsy based on control and time since diagnosis, plus a six-month postponement after diagnosis ^[27]. OpenAI, deepseek, and kimi each reported that no epilepsy-specific Transamerica criteria were found in their reviewed materials ^[28]. These are not necessarily contradictory findings about the company; they are contradictory findings about what is publicly retrievable.

Seizure thresholds also conflict. One independent agent review states Transamerica final expense allows preferred rates with fewer than six seizures in the last 24 months ^[31], while an older state application form asks whether the applicant had more than 12 seizures in the past two years ^[32]. Google flagged this discrepancy directly.

Pricing is unverified across the board. One independent source estimated roughly $23 per month for a 30-year-old non-smoking female and about $29 per month for a male with absence seizures and five or more seizure-free years, for $500,000 of 20-year term ^[33], but that source labels the figures illustrative. No platform produced a verified epilepsy-specific Transamerica rate.

Use-Case-Specific Features and Capabilities

Questions This Section Answers

• What coverage amounts and term lengths does Transamerica offer for a buyer with epilepsy?
• Can a Transamerica term policy be converted to permanent coverage if seizure control changes?

The features most relevant to this buyer are coverage range, exam avoidance, speed, and conversion rights.

Two limitations belong in the same table's context. Trendsetter Super is unavailable in New York ^[35], and final expense death benefits during the first two years are limited to 110% of premiums paid for non-accidental death ^[36]. One independent agent review states whole life is not marketed as favorable for epilepsy applicants ^[37], though that is a single reviewer's assessment rather than a company statement.

Pricing, Fees, Contracts, and Ongoing Costs

Questions This Section Answers

• How much does Transamerica final expense cost per month for a buyer with epilepsy?
• Are there fees or premium increases a buyer with a seizure disorder should expect from Transamerica?

No verified epilepsy-specific Transamerica premium exists in the supplied research. Every platform reported low pricing confidence, and the only concrete figures are non-epilepsy illustrations.

Known cost data points: final expense premiums of roughly $40–$60 per month for a $10,000 policy for a 60-year-old woman in good health ^[38]; a standard annual policy fee cited at about $42.00 (google); and table ratings that add a percentage surcharge to the base standard rate for moderate to poor seizure control (google). One independent source states simplified-issue pricing runs 50–150% above standard rates industry-wide and that fully underwritten term with a table rating can exceed double the standard premium for recent seizures ^[39].

Contract terms to verify: Trendsetter premiums increase after the initial level-premium guarantee period ^[40]; Trendsetter materials identify a suicide limitation during the first two policy years in most states ^[41]; policy forms, riders, issue limits, and availability vary by state ^[41]; and exact free-look, lapse, surrender, conversion, and cancellation provisions must come from the policy contract and state-specific illustration (openai). Rider charges were not identified in reviewed public materials (openai).

Best Suited For

Questions This Section Answers

• Who is Transamerica best suited for among buyers with epilepsy or seizure disorders?
• Is Transamerica a good fit for a buyer with well-controlled absence seizures?

Transamerica is best suited to buyers who want a mainstream carrier with more than one underwriting path and who will accept that eligibility must be tested rather than predicted.

Specifically: applicants seeking roughly $1,000–$50,000 of permanent final-expense coverage (openai); applicants with controlled seizure disorders who want to compare simplified-issue coverage against fully underwritten term (openai); applicants who can work through an agent able to obtain a preliminary underwriting assessment (openai); applicants with well-controlled or absence seizures who may qualify for standard rates ^[43]; applicants with tonic-clonic seizures where Transamerica's described flexibility may produce approval when other carriers decline ^[45]; and buyers who value conversion rights to permanent coverage without a new medical exam ^[47].

Probably Not Best Suited For

Questions This Section Answers

• Who should not choose Transamerica for life insurance with a seizure disorder?
• Is Transamerica a poor fit for buyers with recent or uncontrolled seizures?

Transamerica is probably not the best choice for several profiles.

Buyers needing large income-replacement coverage who can qualify for competitively priced fully underwritten term elsewhere (openai). Applicants with recent, frequent, uncontrolled, or drug-resistant seizures who need a carrier with clearly documented neurological-risk guidelines (openai). Applicants seeking transparent epilepsy-specific acceptance rules or publicly posted premiums (openai, kimi). Applicants with seizures less than four to six months ago, who may face postponed underwriting ^[49]. New York residents seeking Trendsetter Super, which is unavailable there ^[51]. Buyers who want direct online application for final expense or most products, since most processes require an agent and online quotes exist only for Trendsetter Super term ^[52]. And buyers weighing service quality should note that one independent review reported Transamerica's 2025 complaint rate was over four times higher than expected, alongside excellent financial strength ratings ^[53].

When Another Option May Be Better

Questions This Section Answers

• What is a better alternative to Transamerica for a buyer with recent seizures who needs guaranteed acceptance?
• When should a buyer with epilepsy choose a different carrier than Transamerica?

Another option may be better in five situations.

When the buyer needs guaranteed acceptance with no health questions about epilepsy, since Transamerica does not present its final expense or term products as guaranteed-acceptance and states not everyone will qualify ^[55]. When seizures are recent or poorly controlled and the buyer needs an insurer with documented epilepsy-friendly underwriting rather than inferred flexibility (openai, kimi). When the buyer wants published rate classes or a pre-application indication specific to seizure disorders (kimi). When the buyer lives in New York and needs Trendsetter Super specifically ^[56]. When the buyer has stable seizure control and needs substantial coverage, in which case comparing fully underwritten term quotes from multiple carriers before defaulting to final expense is the more rational sequence (openai).

Independent guidance consistently recommends comparing multiple insurers because carriers differ materially in how they evaluate epilepsy, particularly when seizure control, medication history, or recent events are unfavorable ^[57].

Questions to Verify Before Buying

Questions This Section Answers

• What should a buyer confirm with Transamerica before signing an epilepsy life insurance contract?
• How can a buyer with a seizure disorder confirm Transamerica's underwriting outcome before applying?

Ask these before committing:

1. Will Transamerica review the case informally before a formal application or medical-record inquiry (openai)?
2. How does the underwriter evaluate seizure type, date of last seizure, frequency, duration, loss of consciousness, status epilepticus, emergency visits, and injuries (openai)?
3. What seizure-free period is generally required for standard, rated, modified, or declined offers (openai)?
4. How are current anti-seizure medications, medication changes, missed doses, treatment compliance, neurologist follow-up, EEG results, imaging, and driving restrictions evaluated (openai)?
5. Would the recommended product require an exam, labs, attending-physician statement, prescription database review, or medical records (openai)?
6. For final expense, is the benefit immediate or graded for this specific health profile (openai)?
7. What are the exact state-specific premium, face-amount, rider, conversion, lapse, surrender, and cancellation provisions (openai)?
8. For Trendsetter term, when do premiums increase, and what conversion rights apply (openai)?
9. Is the policy available in the buyer's state, including New York or any other excluded jurisdiction ^[60]?
10. Would another carrier offer a better rate or underwriting class for the same documented seizure history (openai)?

Final AI Consensus Verdict

Transamerica is a mixed, not clearly best-in-market, fit for a U.S. consumer with epilepsy or another seizure disorder. Six of seven platforms named it, it averaged rank 2.17, and it reached rank 1 on three platforms, but four of seven platforms rated the fit mixed rather than good or strong.

The strongest reason to consider it is breadth: a simplified-issue final expense path for modest permanent coverage and a fully underwritten term path for larger protection, with conversion rights and no-exam options on parts of the portfolio. The main limitation is opacity. Transamerica does not publicly disclose epilepsy-specific underwriting criteria or rates, and the platforms disagreed about whether such criteria exist in retrievable form at all. Buyers should obtain an agent-assisted preliminary assessment and compare several carriers before purchasing.

How This Review Was Produced

This review was generated from seven platform research responses collected for the run date 2026-09-22, each evaluating which life insurance carriers are worth considering for applicants with epilepsy or a seizure disorder. Transamerica was included because it was named by at least two platforms during ranking discovery; it was named by six of seven. Ranking statistics, fit ratings, product lists, pricing notes, and verification questions were taken from the supplied platform outputs. Company-owned pages and independent reviews were used as cited. No product was purchased, no application was submitted, and no carrier was contacted.

Methodology Limitations

Platform-reported research dates differ from the authoritative run date. Six platforms reported 2026-09-22; deepseek reported 2026-01-15, and deepseek also ran without search enabled, so its claims rest on model knowledge rather than retrieved pages. Platform-reported dates are provenance metadata and do not independently prove freshness.

The supplied URLs were collected from platform responses and were not independently validated at the writing stage. Citations are platform-reported evidence, not independently verified facts. Where a platform supplied no citation for a factual claim, that claim is labeled platform-reported or unverified.

Conflicting product names, pricing, and capabilities were not resolved by guessing. Transamerica's final expense line appears as FE Express Solution, FE Immediate Solution, Easy Solution, and Immediate Solution across sources, and public underwriting guides show different epilepsy decision bands. No reliable public premium quote for an epilepsy applicant can be determined without age, state, coverage amount, smoking status, seizure history, medications, and broader medical information. Product availability, riders, underwriting programs, and terms vary by state. Agreement among AI platforms reflects shared source material and does not prove product quality.